Vertex pharmaceuticals
Vertex shares results from phase 1/2 trial of type 1 diabetes treatment
June 24, 2024Research and Development Diabetes, Vertex pharmaceuticals, clinical trial, diabetes
Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated …
Vertex to acquire Alpine Immune Sciences for $4.9bn
April 11, 2024Business Services Alpine Immune Sciences, Nephrology, Vertex pharmaceuticals, acquisition, nephropathy
Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will …
EC approves Vertex’s Casgevy for sickle cell disease treatment
February 13, 2024Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …
Vertex announces positive results from trial for cystic fibrosis combination treatment
February 6, 2024Research and Development Chronic Diseases, Vertex pharmaceuticals, clinical trial, combination treatment, cystic fibrosis
Vertex Pharmaceuticals has announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor programme, the company’s phase 3 programme for the treatment of …
Vertex Pharma bring in new CFO, shares rise
September 7, 2017Ironwood Pharmaceuticals, Vertex pharmaceuticals, biotech, drugs, pharma, pharmaceutical
Vertex Pharmaceuticals announced the appointment of J&J veteran, Tom Graney, as Senior Vice President and Chief Financial Officer. Graney will …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
